Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma

Journal of Clinical Apheresis

Volumn 27, Issue 5, 2012, Pages 260-262

  Vives, Susana ^a   Sancho, Juan Manuel ^a   Almazán, Francisco ^a   Juncà, Jordi ^a   Grifols, Joan Ramon ^b   Ribera, Josep Maria ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b BANC DE SANG I TEIXITS   (Spain)

Author keywords

CD34+; cell collection; mozobil; solid tumor; young patients

Indexed keywords

BEVACIZUMAB; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; PLERIXAFOR; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; APHERESIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; EWING SARCOMA; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD STEM CELL; STEM CELL MOBILIZATION; TREATMENT RESPONSE;

ADOLESCENT; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; SARCOMA, EWING; TREATMENT OUTCOME;

EID: 84867234128     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.21234     Document Type: Article

References (10)

1. Duong HK, Bolwell BJ, Rybicki L, Koo A, Hsi ED, Figueroa P, Dean R, Pohlman B, Kalaycio H, Andresen S, Sobecks R, Copelan E,. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield. J Clin Apher 2011; 26: 111-115.
2. Ford CD, Green W, Warenski S, Petersen FB,. Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplant 2004; 33: 901-905.
3. Stewart DA, Smith C, MacFarland R, Calandra G,. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 39-46.
4. Di Persio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwite M, Cooper D, Bridger G, Calandra G, 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
5. Di Persio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G, 3101 Investigaors. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
6. Kobold S, Isernhagen J, Hübel K, Kilic N, Bogner C, Frickhofen N, Bokemeyer C, Fiedler W,. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients. Bone Marrow Transplant 2011; 46: 1053-1056.
7. Cardenoux C, Deméocq F, Kanold J, Merlin E, Oudot C, Piquet C, Roussanne MC,. Pegfilgastrim plus AMD 3100 for stem-cell mobilization in children. Pediatr Blood Cancer 2010; 55: 769.
8. Sevilla J, Schiavello E, Madero L, Pardeo M, Guggiari E, Baragaño M, Luksch R, Massimino M,. Priming of hematopoietic progenitor cells by plerixafor and filgastrim in children with previous failure of mobilization with chemotherapy and/or cytokine treatment. J Pediatr Hematol Oncol 2012; 34: 146-150.
9. Modak S, Cheung IY, Kushner BH, Kramer K, Reich L, Cheung NK,. Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatr Blood Cancer 2012; 58: 469-471.
10. Kushner BH, Meyers PA,. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001; 19: 870-880.